Affiliation:
1. Department of Medical Oncology, MVR Cancer Centre and Research Institute, Calicut, Kerala, India
Abstract
AbstractOvarian malignancy is the seventh most frequently diagnosed cancer among women. The most common type is epithelial ovarian cancer. Several subtypes with distinct biological and molecular properties exist, and there is inconsistency in availability of and access to different modalities of treatment. The standard first-line management is combining surgery and platinum-based chemotherapy. Most of them are diagnosed at an advanced stage due to which they have poor outcomes. The existing screening tests have a low predictive value. Even with the best available upfront treatment, high rates of recurrences are observed. As a result, there have been major advances in the treatment of recurrences with the development of anti-angiogenic agents and PARP inhibitors. It has led to the improvement in survival and quality of life among the relapsed epithelial ovarian cancers. This review is focused on the management of recurrent epithelial ovarian cancers and future directions based on current evidence. The application of a personalized and structured approach will meaningfully bring changes in the paradigm of care in these groups of patients.
Subject
Oncology,Pediatrics, Perinatology and Child Health
Reference83 articles.
1. Extending the platinum-free interval: the impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer;L E Dockery;Gynecol Oncol,2019
2. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse;E Pujade-Lauraine;J Clin Oncol,2010
3. Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study;S Pignata;J Clin Oncol,2017
4. Clinical trials in recurrent ovarian cancer;M Friedlander;Int J Gynecol Cancer,2011
5. Molecular mechanisms of resistance and toxicity associated with platinating agents;C A Rabik;Cancer Treat Rev,2007